Journal article · 2020 · Open access

Alzheimer's disease drug development pipeline: 2020

Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, Kate Zhong

Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), e12050 · Published 1 January 2020 · DOI 10.1002/trc2.12050

Free PDFView at the publisherCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2020” is a 2020 journal article by Jeffrey L. Cummings and 4 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 597 citations as of 15 November 2026, which puts it in the top 1% of works published in 2020 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
597
Most cited in
2021 (192)
Field-weighted impact
41.96
References
49
Authors
5

Abstract

INTRODUCTION: Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD. We use the Common Alzheimer's and Related Dementias Research Ontology (CADRO) to classify treatment targets and mechanisms of action. We review our annual pipeline reports for the past 5 years to provide longitudinal insight into clinical trials and drug development for AD. METHODS: We reviewed ClinicalTrials.gov as of February 27, 2020, and identified all trials of pharmacologic agents currently being developed for treatment of AD as represented on this widely used U.S. Food and Drug Administration registry. RESULTS: There are 121 agents in clinical trials for the treatment of AD. Twenty-nine agents are in 36 Phase 3 trials, 65 agents are in 73 Phase 2 trials, and 27 agents are in 27 Phase 1 trials. Twelve agents in trials target cognitive enhancement and 12 are intended to treat neuropsychiatric and behavioral symptoms. There are 97 agents in disease modification trials. Compared to the 2019 pipeline, there is an increase in the number of disease-modifying agents targeting pathways other than amyloid or tau. DISCUSSION: The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. Review of clinical trials over the past 5 years show that there is progressive emphasis on non-amyloid targets, including candidate treatments for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. There has been a marked growth in repurposed agents in the pipeline.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Lee, G., Ritter, A. R., Sabbagh, M. N., & Zhong, K. (2020). Alzheimer's disease drug development pipeline: 2020. Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), e12050. https://doi.org/10.1002/trc2.12050

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2020.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 6, no. 1, 2020, p. e12050. https://doi.org/10.1002/trc2.12050.

Chicago

Cummings, Jeffrey L., Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, and Kate Zhong. 2020. “Alzheimer's disease drug development pipeline: 2020.” Alzheimer s & Dementia Translational Research & Clinical Interventions 6 (1): e12050. https://doi.org/10.1002/trc2.12050.

Harvard

Cummings, J. L. et al. (2020) ‘Alzheimer's disease drug development pipeline: 2020’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), p. e12050. doi:10.1002/trc2.12050.

IEEE

J. L. Cummings, G. Lee, A. R. Ritter, M. N. Sabbagh, and K. Zhong, “Alzheimer's disease drug development pipeline: 2020,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 6, no. 1, p. e12050, 2020, doi: 10.1002/trc2.12050.

BibTeX

@article{cummings2020alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2020}},
  author    = {Cummings, Jeffrey L. and Lee, Garam and Ritter, Aaron R. and Sabbagh, Marwan Noel and Zhong, Kate},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2020},
  volume    = {6},
  number    = {1},
  pages     = {e12050},
  doi       = {10.1002/trc2.12050},
  url       = {https://doi.org/10.1002/trc2.12050}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20203232
2021192192
2022162162
20235656
20246060
20255252
20264343

Its field-weighted citation impact is 41.96: it has been cited 41.96 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • disease-modifying therapy
  • amyloid
  • tau protein
  • cognitive enhancement
  • neuropsychiatric symptoms

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Lee, G., Ritter, A. R., Sabbagh, M. N., & Zhong, K. (2020). Alzheimer's disease drug development pipeline: 2020. Alzheimer s & Dementia Translational Research & Clinical Interventions, 6(1), e12050. https://doi.org/10.1002/trc2.12050

How many times has this paper been cited?

597 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Garam Lee, Aaron R. Ritter, Marwan Noel Sabbagh, Kate Zhong.

What is the DOI of this paper?

10.1002/trc2.12050. The permanent link is https://doi.org/10.1002/trc2.12050.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.